Kirsten Rat Sarcoma Viral Oncogene Homolog ( KRAS ) Mutation Testing Trends, Prevalence, and Outcomes in Metastatic, Non‐Squamous Non‐Small Cell Lung Cancer (Non‐ SQ NSCLC ) Patients in Queensland, Australia From 2014–2023

Key Points

• To analyze trends and prevalence of KRAS mutation testing in non-squamous non-small cell lung cancer patients in Queensland from 2014 to 2023.
• Conducted a longitudinal analysis of KRAS mutation testing rates
• Collected data from patients diagnosed with metastatic non-squamous non-small cell lung cancer
• Compared findings with existing literature on KRAS mutations
• Significant improvement in KRAS mutation testing rates over time
• Characteristics of KRAS mutation-positive patients aligned with published literature